Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor

International Immunopharmacology

Volumn 12, Issue 1, 2012, Pages 50-58

  Kobayashi, Miki ^a   Kubo, Satoshi ^a   Hirano, Yasuno ^a   Kobayashi, Seiji ^a   Takahashi, Koichiro ^a   Shimizu, Yasuaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Airway hyperresponsiveness (AHR); ASP3258; Bronchoalveolar lavage (BAL); Brown Norway (BN) rat; Guinea pig; Phosphodiesterase 4 (PDE4)

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ASP 3258; CILOMILAST; OVALBUMIN; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CELL INFILTRATION; CONTROLLED STUDY; DRUG POTENCY; EOSINOPHIL; FEMALE; GUINEA PIG; HISTOLOGY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINOPYRIDINES; ANIMALS; ANTI-ASTHMATIC AGENTS; BENZAMIDES; BRONCHIAL HYPERREACTIVITY; BRONCHOCONSTRICTION; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOPROPANES; DISEASE MODELS, ANIMAL; EOSINOPHILS; FEMALE; GUINEA PIGS; LUNG; MALE; NAPHTHYRIDINES; NITRILES; OVALBUMIN; PHOSPHODIESTERASE 4 INHIBITORS; RATS; TRACHEA;

EID: 84856087428     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.10.008     Document Type: Article

References (38)

1. P.J. Barnes Cytokine-directed therapies for the treatment of chronic airway diseases Cytokine Growth Factor Rev 14 2003 511 522 (Pubitemid 37296024)
2. J.F. Donohue Therapeutic responses in asthma and COPD. Bronchodilators Chest 126 2004 125S 137S [discussion 59S-61S] (Pubitemid 39093402)
3. Global strategy for asthma management and prevention - updated. 2009.
4. P.J. Barnes, and I.M. Adcock Glucocorticoid resistance in inflammatory diseases Lancet 373 2009 1905 1917
5. M.M. Teixeira, R.W. Gristwood, N. Cooper, and P.G. Hellewell Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 18 1997 164 171
6. J.E. Souness, D. Aldous, and C. Sargent Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors Immunopharmacology 47 2000 127 162 (Pubitemid 30394536)
7. D. Spina Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease Drugs 63 2003 2575 2594 (Pubitemid 37491561)
8. J.E. Souness, and S. Rao Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases Cell Signal 9 1997 227 236 (Pubitemid 27271642)
9. R.J. Heaslip, and D.Y. Evans Emetic, central nervous system, and pulmonary activities of rolipram in the dog Eur J Pharmacol 286 1995 281 290
10. T.J. Torphy, M.S. Barnette, D.C. Underwood, D.E. Griswold, S.B. Christensen, and R.D. Murdoch Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic Pulm Pharmacol Ther 12 1999 131 135 (Pubitemid 29366508)
11. M. Kobayashi, S. Kubo, M. Iwata, Y. Ohtsu, K. Takahashi, and Y. Shimizu ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity Int Immunopharmacol 11 2011 732 739
12. A. Hatzelmann, and C. Schudt Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro J Pharmacol Exp Ther 297 2001 267 279 (Pubitemid 32242587)
13. D.C. Underwood, S. Bochnowicz, R.R. Osborn, C.J. Kotzer, M.A. Luttmann, and D.W. Hay Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig J Pharmacol Exp Ther 287 1998 988 995 (Pubitemid 29131612)
14. S. Kubo, M. Kobayashi, M. Iwata, K. Takahashi, K. Miyata, and Y. Shimizu Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs Eur J Pharmacol 659 2011 79 84
15. T. Yoshino, J. Ishikawa, K. Ohga, T. Morokata, R. Takezawa, and H. Morio YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models Eur J Pharmacol 560 2007 225 233 (Pubitemid 46341302)
16. Y. Arakida, K. Ohga, Y. Okada, H. Morio, K. Suwa, and M. Yokota Effect of combined leukotriene D(4) and thromboxane A(2) receptor antagonist on mediator-controlled resistance in guinea pigs Eur J Pharmacol 403 2000 169 179
17. 2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo Pulm Pharmacol Ther 2008 360 369 [2007/11/06 ed] (Pubitemid 351312679)
18. J. Bousquet, P. Chanez, J.Y. Lacoste, G. Barneon, N. Ghavanian, and I. Enander Eosinophilic inflammation in asthma N Engl J Med 323 1990 1033 1039 (Pubitemid 20336962)
19. M. Werner-Klein, R. Goggel, A. Westhof, and K.J. Erb Development and characterisation of a novel and rapid lung eosinophil influx model in the rat Pulm Pharmacol Ther 21 2008 648 656 (Pubitemid 351982015)
20. A. Trifilieff, D. Wyss, C. Walker, L. Mazzoni, and R. Hersperger Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities J Pharmacol Exp Ther 301 2002 241 248 (Pubitemid 34250301)
21. M.A. Giembycz Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors Curr Opin Pharmacol 5 2005 238 244 (Pubitemid 40674245)
22. D. Spina PDE4 inhibitors: current status Br J Pharmacol 155 2008 308 315
23. A. Robichaud, C. Savoie, P.B. Stamatiou, N. Lachance, P. Jolicoeur, and R. Rasori Assessing the emetic potential of PDE4 inhibitors in rats Br J Pharmacol 135 2002 113 118 (Pubitemid 34102104)
24. A. Robichaud, C. Savoie, P.B. Stamatiou, F.D. Tattersall, and C.C. Chan PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway Neuropharmacology 40 2001 262 269
25. F.L. Ricciardolo, F. Nijkamp, V. De Rose, and G. Folkerts The guinea pig as an animal model for asthma Curr Drug Targets 9 2008 452 465 (Pubitemid 352025202)
26. D.S. Bundschuh, M. Eltze, J. Barsig, L. Wollin, A. Hatzelmann, and R. Beume In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor J Pharmacol Exp Ther 297 2001 280 290 (Pubitemid 32242588)
27. R.P. Schleimer Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma Am Rev Respir Dis 141 1990 S59 S69
28. R.P. Schleimer, E.S. Schulman, D.W. MacGlashan Jr. , S.P. Peters, E.C. Hayes, and G.K. Adams III Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells J Clin Invest 71 1983 1830 1835 (Pubitemid 13056786)
29. P.M. O'Byrne, and D.S. Postma The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Asthma Research Group Am J Respir Crit Care Med 159 1999 S41 S63
30. S.G. Dastidar, A. Ray, R. Shirumalla, D. Rajagopal, S. Chaudhary, and K. Nanda Pharmacology of a novel, orally active PDE4 inhibitor Pharmacology 83 2009 275 286
31. M.M. Billah, N. Cooper, M. Minnicozzi, J. Warneck, P. Wang, and J.A. Hey Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2- (trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor J Pharmacol Exp Ther 302 2002 127 137 (Pubitemid 34680430)
32. M.S. Barnette Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD) Prog Drug Res 53 1999 193 229 (Pubitemid 29515642)
33. C. Walker, M.K. Kaegi, P. Braun, and K. Blaser Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity J Allergy Clin Immunol 88 1991 935 942
34. A.J. Wardlaw, S. Dunnette, G.J. Gleich, J.V. Collins, and A.B. Kay Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity Am Rev Respir Dis 137 1988 62 69 (Pubitemid 18032827)
35. S.H. Gavett, D.J. O'Hearn, C.L. Karp, E.A. Patel, B.H. Schofield, and F.D. Finkelman Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice Am J Physiol 272 1997 L253 L261
36. L.C. Borish, H.S. Nelson, J. Corren, G. Bensch, W.W. Busse, and J.B. Whitmore Efficacy of soluble IL-4 receptor for the treatment of adults with asthma J Allergy Clin Immunol 107 2001 963 970 (Pubitemid 32523334)
37. P.S. Thomas Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma Immunol Cell Biol 79 2001 132 140 (Pubitemid 32281083)
38. P.S. Thomas, and G. Heywood Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma Thorax 57 2002 774 778 (Pubitemid 34984975)